<?xml version="1.0" ?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:seo="http://purl.org/seo/elements/1.0/" version="2.0">
	<channel>
		<title>Okogen News Releases</title>
		<link>https://feeds.newsfilecorp.com/company/12792</link>
		<description>Latest news from Okogen, as distributed by TMX Newsfile.</description>
		<language>en</language>
		<copyright>CopyRight (c) 2026, Newsfile Corp. All Rights Reserved.</copyright>
		<managingEditor>office@newsfilecorp.com (Newsfile Corp.)</managingEditor>
		<webMaster>office@newsfilecorp.com (Newsfile Corp.)</webMaster>
		<lastBuildDate>Mon, 02 Nov 2026 14:35:19 -0500</lastBuildDate>
		<image>
			<url>https://images.newsfilecorp.com/logos/12792.jpg</url>
			<title>Okogen News Releases</title>
			<link>https://feeds.newsfilecorp.com/company/12792</link>
		</image>
		<atom:link rel="self" type="application/rss+xml" href="https://feeds.newsfilecorp.com/company/12792"/>
		<item xml:lang="en">
			<title>Okogen Announces First Patient Dosed in Phase 1/2 EMERALD Trial Evaluating Treyegen for Acute Infectious Conjunctivitis</title>
			<link>https://www.newsfilecorp.com/release/322071/Okogen-Announces-First-Patient-Dosed-in-Phase-12-EMERALD-Trial-Evaluating-Treyegen-for-Acute-Infectious-Conjunctivitis</link>
			<description>      Plano, Texas--(Newsfile Corp. - November 2, 2026) - Okogen, Inc., a clinical-stage biotechnology company developing a host-directed antiviral platform, today announced that the first patient has been dosed in the EMERALD Trial, its multicenter      Phase 1/2 clinical study evaluating Treyegen (OKG-0303) for acute infectious conjunctivitis. First dosing occurred at Ambade Eye Hospital in Nagpur, India.          To view the full announcement, including downloadable images, bios, and more,...&lt;img src="https://api.newsfilecorp.com/newsinfo/322071/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Mon, 02 Nov 2026 10:50:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/322071</guid>
		</item>
		<item xml:lang="en">
			<title>Okogen Receives CDSCO Authorization to Advance the EMERALD Phase 1/2 Study of Treyegen (OKG-0303) for Acute Infectious Conjunctivitis</title>
			<link>https://www.newsfilecorp.com/release/317640/Okogen-Receives-CDSCO-Authorization-to-Advance-the-EMERALD-Phase-12-Study-of-Treyegen-OKG0303-for-Acute-Infectious-Conjunctivitis</link>
			<description>      Plano, Texas--(Newsfile Corp. - October 6, 2026) - Okogen, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases, today announced that the Central Drugs Standard Control Organisation      (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, the Company's Phase 1/2 clinical trial evaluating Treyegen (OKG-0303) for the treatment of acute      infectious conjunctivitis.          To view the full...&lt;img src="https://api.newsfilecorp.com/newsinfo/317640/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 06 Oct 2026 09:28:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/317640</guid>
		</item>
	</channel>
</rss>
